نتائج البحث - Terrance D. Barrett

  • يعرض 1 - 7 نتائج من 7
تنقيح النتائج
  1. 1
    RETRACTED: Obestatin reduces food intake and suppresses body weight gain in rodents

    RETRACTED: Obestatin reduces food intake and suppresses body weight gain in rodents حسب Guy Lagaud, Andy Young, Auzon Acena, Magda F. Morton, Terrance D. Barrett, Nigel P. Shankley

    منشور في 2007
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron Homeostasis

    TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron Homeostasis حسب Tomas Ganz, Elizabeta Nemeth, Stefano Rivella, Paul Goldberg, Andrew R. Dibble, Michael L. McCaleb, Shuling Guo, Brett P. Monia, Terrance D. Barrett

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus

    Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus حسب Gemma A. Figtree, Karin Rådholm, Terrance D. Barrett, Vlado Perkovic, Kenneth W. Mahaffey, Dick de Zeeuw, Greg Fulcher, David R. Matthews, Wayne Shaw, Bruce Neal

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

    Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials حسب Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D. Barrett, Michele A. Weidner‐Wells, Hsiaowei Deng, David R. Matthews, Bruce Neal

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus

    Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus حسب Karin Rådholm, Gemma A. Figtree, Vlado Perkovic, Scott D. Solomon, Kenneth W. Mahaffey, Dick de Zeeuw, Greg Fulcher, Terrance D. Barrett, Wayne Shaw, Mehul Desai, David R. Matthews, Bruce Neal

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats

    Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats حسب Terrance D. Barrett, Heather L. Palomino, Theresa I. Brondstetter, Kimon C. Kanelakis, Xiaodong Wu, Wen Yan, Katherine P Merton, Freddy Schoetens, Ying Jing, Judy Skaptason, Jingjin Gao, Da‐Thao Tran, Hariharan Venkatesan, Mark D. Rosen, Nigel P. Shankley, Michael H. Rabinowitz

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues

    Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues حسب Mark D. Rosen, Hariharan Venkatesan, Hillary M. Peltier, Scott D. Bembenek, Kimon C. Kanelakis, Lucy X. Zhao, Barry E. Leonard, Frances M. Hocutt, Xiaodong Wu, Heather L. Palomino, Theresa I. Brondstetter, Peter V. Haugh, Laurence Cagnon, Wen Yan, L. Liotta, Andrew Young, Tara Mirzadegan, Nigel P. Shankley, Terrance D. Barrett, Michael H. Rabinowitz

    منشور في 2010
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: